SA
TCRT logo
Alaunos Therapeutics, Inc.(TCRT)
Closing price · checked 8:39 PM ETAbout this dataData status
$1.66▲0.07 (4.40%)
Extended:$1.66+0.00 (+0.00%)· 8:39 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →
Next report

Mar 9 2027in 107 days

EPS estimate

($0.02)

Revenue estimate

—

EPS beats

9 of last 10

Earnings SurpriseEPS, actual vs estimateLatest +84.9%

How far reported EPS beat (+) or missed (−) the analyst estimate that stood when each report landed.

2024: -8.9%2024: 75.6%2024: 84.2%2024: 84.4%2025: 89.8%2025: 89.6%2025: 88.2%2025: 88.8%2026: 89.1%2026: 84.9%75.6%84.4%89.6%88.8%84.9%
Apr 2 2024Nov 16 2026
ReportedEPS estEPS actualSurpriseRevenue estRevenue actualSurprise
Nov 16 2026($2.05)($0.31)+84.9%———
Aug 14 2026—($0.41)————
May 15 2026—($0.59)————
Mar 31 2026($3.69)($0.40)+89.1%$3000$3000+0.0%
Nov 14 2025($4.90)($0.55)+88.8%———
Aug 14 2025($5.33)($0.63)+88.2%———
May 15 2025($6.44)($0.67)+89.6%—$2000—
Mar 31 2025($4.50)($0.46)+89.8%—$4000—
Nov 14 2024($4.50)($0.70)+84.4%———
Aug 14 2024($4.50)($0.71)+84.2%—$4000—
May 15 2024($4.50)($1.10)+75.6%—$1000—
Apr 2 2024($0.45)($0.49)-8.9%—$1000—

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+151.81%
EPS—
FY2028
Rev-100.00%
EPS—
FY2029
Rev+12.54%
EPS—
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$88M$220M$7,127$8,021$9,027
Low$88M$220M$7,127$8,021$9,027
High$88M$220M$7,127$8,021$9,027
EBITDA Avg$11M$32M$20M$9M$517,101
Low$11M$32M$20M$9M$517,101
High$11M$32M$20M$9M$517,101
EBIT Avg$250,662$-4M$-9M$-14M$-18M
Low$250,662$-4M$-9M$-14M$-18M
High$250,662$-4M$-9M$-14M$-18M
Net Income Avg$-389,671$-4M$-9M$-14M$-18M
Low$-389,671$-4M$-9M$-14M$-18M
High$-389,671$-4M$-9M$-14M$-18M
EPS Avg$-0.20$-2.25$-4.80$-7.35$-9.45
Low$-0.20$-2.25$-4.80$-7.35$-9.45
High$-0.20$-2.25$-4.80$-7.35$-9.45
Analysts (Rev / EPS)1 / 11 / 11 / 11 / 11 / 1
Quarterly
MetricQ4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028Q3 2028
Revenue Avg————————
Low————————
High————————
EBITDA Avg————————
Low————————
High————————
EBIT Avg————————
Low————————
High————————
Net Income Avg$-52,093$-911,632$-1M$-2M$-2M$-20M$-20M$-17M
Low$-52,093$-911,632$-1M$-2M$-2M$-20M$-20M$-17M
High$-52,093$-911,632$-1M$-2M$-2M$-20M$-20M$-17M
EPS Avg$-0.02$-0.35$-0.45$-0.60$-0.85$-7.71$-7.80$-6.34
Low$-0.02$-0.35$-0.45$-0.60$-0.85$-7.71$-7.80$-6.34
High$-0.02$-0.35$-0.45$-0.60$-0.85$-7.71$-7.80$-6.34
Analysts (Rev / EPS)— / 1— / 1— / 1— / 1— / 1— / 1— / 1— / 1

Q4 2022
Checking for summary...

Last reported Earnings history refreshes daily; a new report appears within about 2 daysAbout this data

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.